Arasappan, Ashok published the artcile5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors, Quality Control of 56-05-3, the publication is Bioorganic & Medicinal Chemistry Letters (2012), 22(9), 3229-3234, database is CAplus and MEDLINE.
Based on a previously identified HCV replication (replicase) inhibitor I, SAR efforts were conducted around the pyrimidine core to improve the potency and pharmacokinetic profile of the inhibitors. A benzothiazole moiety was found to be the optimal substituent at the pyrimidine 5-position. Due to potential reactivity concern, the 4-chloro residue was replaced by a Me group with some loss in potency and enhanced rat in vivo profile. Extensive investigations at the C-2 position resulted in identification of compound II that demonstrated very good replicon potency, selectivity and rodent plasma/target organ concentration Inhibitor II also demonstrated good plasma levels and oral bioavailability in dogs, while monkey exposure was rather low. Chem. optimization towards a practical route to install the benzothiazole moiety resulted in an efficient direct C-H arylation protocol.
Bioorganic & Medicinal Chemistry Letters published new progress about 56-05-3. 56-05-3 belongs to pyrimidines, auxiliary class Pyrimidine,Chloride,Amine,API, name is 2-Amino-4,6-dichloropyrimidine, and the molecular formula is C4H3Cl2N3, Quality Control of 56-05-3.
Referemce:
https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimidine,
Pyrimidine – Wikipedia